

REVIEW

Open Access



Gut–kidney crosstalk in septic acute kidney injury

Jingxiao Zhang^{1,3}, Ghada Ankawi^{2,3}, Jian Sun¹, Kumar Digvijay^{3,6}, Yongjie Yin^{1*}, Mitchell H. Rosner⁴ and Claudio Ronco^{3,5}

Abstract

Sepsis is the leading cause of acute kidney injury (AKI) in the intensive care unit (ICU). Septic AKI is a complex and multifactorial process that is incompletely understood. During sepsis, the disruption of the mucus membrane barrier, a shift in intestinal microbial flora, and microbial translocation may lead to systemic inflammation, which further alters host immune and metabolic homeostasis. This altered homeostasis may promote and potentiate the development of AKI. As part of this vicious cycle, when AKI develops, the clearance of inflammatory mediators and metabolic products is decreased. This will lead to further gut injury and breakdown in mucous membrane barriers. Thus, changes in the gut during sepsis can initiate and propagate septic AKI. This deleterious gut–kidney crosstalk may be a potential target for therapeutic maneuvers. This review analyses the underlying mechanisms in gut–kidney crosstalk in septic AKI.

Keywords: Sepsis, AKI, Septic AKI, Gut–kidney crosstalk, Inflammation

Background

Acute kidney injury (AKI) is a serious complication in critically ill patients and its development is associated with a high rate of mortality and morbidity as well as increased costs [1]. Sepsis is the leading cause of AKI in the intensive care unit (ICU), and 45 to 70% of all AKI is associated with sepsis [2]. Dialysis requiring AKI, when associated with distant organ dysfunction such as cardiac or respiratory failure, is associated with mortality rates as high as 60 to 80% [3, 4]. Septic AKI is a complex and multifactorial process, and our understanding of its pathogenesis remains incomplete [5]. The current understanding of septic AKI involves: microcirculatory abnormalities, renal tubular epithelial cell metabolic dysfunction and injury, and inflammatory changes [6].

Inflammation is a prominent component of septic AKI. Sepsis and inflammation at the tissue and cellular levels are associated with decreased levels of intracellular adenosine triphosphate (ATP) and with mitochondrial injury in the kidney [7]. It has been well described that higher

cytokine concentrations are associated with slower renal recovery from AKI and increased mortality rates [8, 9].

The gastrointestinal tract (gut) is the most common source of secondary infections which occur predominately in the later stages of sepsis. The gut is home to 70–80% of the body's immune cells and at least hundreds of different microbiome species [10]. In septic patients, inflammation and hypoperfusion play an important role in the pathophysiology of gut injury [11]. Gut injury may lead to impaired gut barrier function, which may result in translocation of bacteria and toxins from the intestinal lumen to the mesenteric lymph and systemic circulation. Subsequently, this bacterial translocation may amplify the systemic inflammatory response and contribute to multiple organ failure and death [12]. This dysregulated crosstalk between the gut's epithelium, immune system, endogenous microflora, and kidney may lead to worsening of systemic inflammation and potentiation of AKI [13] (Fig. 1).


The understanding of the gut's role in initiating septic AKI has led to potential novel therapeutic targets that are currently under investigations. In this review, we summarize the underlying mechanisms of gut–kidney crosstalk in septic AKI.

* Correspondence: yinyongjie2003@sina.cn

¹Department of Emergency and Critical Care Medicine, The Second Hospital of Jilin University, Changchun, China

Full list of author information is available at the end of the article






The effect of septic AKI on gastrointestinal function

During septic AKI, increased inflammatory cytokines as well as impairment in the clearance of water and metabolic products (urea in particular) can cause gut injury (Fig. 2). Specifically, increased inflammatory cytokines can damage gut barrier function and increase permeability. The gut's barrier function is due to apical tight junctions and junctional adhesion molecules (JAM), which prevent luminal contents from escaping into the local extra-luminal environment. During septic AKI, increased levels of cytokines can act on these junctional complexes to modulate permeability [14]. Intestinal hyper-permeability may result when sepsis alters the expression of zonulaoccludens 1 (ZO-1), any one of multiple claudin isoforms, or occludin in the tight junction complex. Alternatively, hyper-permeability may be induced by altering expression of components of JAM [14]. Activation of myosin light chain kinase (MLCK) by cytokines can also worsen para-cellular permeability. MLCK phosphorylates myosin light chain, which results in contraction or opening of the apical tight junction [15]. MLCK activation is associated with an increase in interleukin (IL)-6, tumor necrosis factor α (TNF- α), and IL-1 β . The

net result is an increase in intestinal permeability. The increased intestinal permeability leads to an amplification of the systemic inflammatory response in a positive feedback response. The increased systemic inflammation further promotes kidney injury.

During septic AKI, the dysfunction in clearance of metabolic products and water can also directly weaken the gut barrier and increase gut permeability. In septic AKI, kidney dysfunction (with resulting retention of uremic solutes, urea, sodium, and water) as well as aggressive fluid resuscitation can cause a dramatic increase in gut wall edema. This can cause disruption of the colonic epithelial tight junction apparatus [16, 17]. Urea diffuses from the blood into the gut lumen and is metabolized by gut bacterial urease to ammonia ($\text{CO}(\text{NH}_2)_2 + \text{H}_2\text{O} \rightarrow \text{CO}_2 + 2\text{NH}_3$). The ammonia is converted into caustic ammonium hydroxide ($\text{NH}_3 + \text{H}_2\text{O} \rightarrow \text{NH}_4\text{OH}$), which is capable of disrupting tight junction proteins that seal the gap between epithelial cells [17]. Breakdown of this protein triggers influx of luminal toxins as well as bacterial translocation, thus promoting local and systemic inflammation and further damaging the gut's barrier function.



Increased cytokine levels in septic AKI can lead to dysregulation of gut stem cell proliferation/apoptosis

Toll-like receptors (TLRs) which act as pathogen receptors are expressed on various types of epithelial cells, including in the kidney and gut [13, 18]. Intestinal stem cells express TLR4, which regulates whether they proliferate or die by apoptosis [19]. On a cellular level, crypt proliferation is markedly decreased and both crypt and villus apoptosis are simultaneously increased following sepsis [20]. Although epithelial migration is slowed in critical illness in a TLR4-dependent manner, changes in proliferation and apoptosis overwhelm this slowed migration of cells, resulting in a marked diminution of villus length during sepsis [21]. Simultaneously, critical illness induces global alterations in the mucus layer (reduced thickness, diminished luminal coverage, and poor adherence) and altered gut barrier function [22]. Furthermore, increased cytokine concentrations seen in septic AKI can impair gut cell regeneration and stimulate apoptosis in a TLR4-dependent manner [23]. The increased inflammatory cytokine levels can also cause gut cell apoptosis directly. The net result is that gut apoptosis can enhance hyper-permeability, bacterial translocation, and expansion of the inflammatory response [24].

To summarize, during septic AKI, increased inflammatory cytokine concentrations and retention of urea as well as other metabolites and water can damage the gut barrier, leading to increased permeability. Impaired gut barrier function results in translocation of bacteria and toxins from the intestinal lumen to the mesenteric lymph

system and to the systemic circulation. Subsequently, this bacterial translocation may amplify the systemic inflammatory response and contribute to multiple organ failure and death [12].

The role of the microbiome in gut-kidney crosstalk

The intestinal microbiome is made up of more than 100 trillion microorganisms, and is continuously changing over the life of the host, based on diet, age, drug intake, and presence or absence of disease [25]. Increasingly, it is recognized that the microbiome plays a crucial role in the maintenance of health and that alterations in the type, number, and function of microorganisms in the microbiome can have a critical role on survival in critical illness [26]. During septic AKI, elevation in inflammatory cytokine levels as well as ischemia can induce changes in the constituent organisms that make up the microbiome of the gut. Importantly, the severity of inflammation can be modulated by the microbiome [25]. For instance, microbes or microbial products can actively change TLR expression in most cellular compartments of the gut tract, and this alters the host's ability to sense and respond to the microbiota. Several other changes occur in gut physiology in septic patients, due to either extrinsic factors (antibiotics and parenteral nutrition) or intrinsic factors (systemic inflammation and gut leakage). These changes, in turn, influence the composition of the enteric flora [27]. A massive loss of microbe diversity occurs in patients with severe sepsis, particularly loss of anaerobic diversity [28]. For instance,

[44] and in **facilitating tissue repair** [45]. Infection causes **monocytes** to migrate and **infiltrate** into organs where they **differentiate** via M1 or M2 pathways into **pathogen-killing** or **tissue-repair phenotypes**, respectively. Therefore, strategies that limit early macrophage infiltration or activation may represent a novel approach in the prevention or treatment of AKI in septic patients. However, the signaling pathway involved in the repair mechanism of M2 macrophages needs further investigation [46]. During sepsis, as the gut barrier function is impaired, bacteria translocation and expanding inflammation change the immune microenvironment, which may determine the fate of macrophage differentiation in the gut, kidney, or other distant organs into a more pro-inflammatory phenotype.

Targeting the microbiome for therapeutic gain in gut-kidney crosstalk

As the gut plays an important role in the progression of inflammation and septic AKI, efforts to modulate the gut microbiome and barrier function to improve outcomes make great sense. Strategies include intake of live microbiota, addition of the necessary nutrients for microbiota regeneration, and administration of exogenous supplements such as **SCFAs** that are the **products of microbiota**. Selective decontamination of the digestive tract, probiotics, phosphate, and SCFAs are the most studied interventions in this regard and targeting the microbiome for therapeutic gain to regulate the immune function is a promising strategy to improve outcomes in sepsis. However, human data are still evolving in this therapeutic area.

Selective decontamination of the digestive tract

Selective decontamination of the digestive tract (SDD) uses **non-absorbable microbials**, which are applied daily in the **oropharynx** and the **gastrointestinal** tract. The aim of this intervention is to **prevent** secondary **colonization** and **overgrowth** of potential bacterial pathogens while **preserving the anaerobic** microbiota, thereby preventing excess infectious disease in critically ill patients [47, 48]. As **90% of the normal anaerobic flora is lost** after a sudden insult such as sepsis [29], the addition of SDD to a septic AKI patient is promising to **rebuild the gut's barrier**, microbiome, and immune function. The aim of this intervention is to **break down the continuous cycle** of injury followed by amplification of inflammation that occurs in the gut-kidney crosstalk pathway [32]. A comprehensive systematic review and network meta-analysis [48], which encompasses more than **60 clinical studies** and ten meta-analyses, suggested that **SDD can prevent noscomial infections** in critically ill patients and decreases **overall mortality** rates. However, **randomized controlled trials** are still **needed** in this area.

Probiotics

Probiotics are **live bacteria** and **yeasts that**, when administered in adequate amounts, confer a health benefit on the host. Although their clinical use is rising, data on efficacy are still emerging. In a murine cecal ligation and perforation model of sepsis, the administration of the probiotics *Lactobacillus rhamnosus* GG (LGG) and *Bifidobacterium longum* (BL) improved mortality following sepsis and prevented sepsis-induced changes in gut epithelial apoptosis and proliferation [49]. Additionally, probiotics can attenuate growth of pathogenic intestinal bacteria, potentially limiting endotoxin production and preventing bacteremia [50]. As a corollary to probiotic administration, there is also increasing evidence that fecal microbiota transplantation is significantly more effective in the treatment of recurrent *Clostridium difficile* infection than standard antibiotic therapy by increasing fecal bacterial diversity in recipients [51].

Short-chain fatty acids


SCFAs are **microbial metabolic products** of **dietary fibers**, and the most studied SCFAs are **butyrate**, **propionate**, and **acetate**. These metabolites are sensed by the G-protein-coupled receptors (GPR) on intestinal epithelium and can also diffuse across the epithelium [13, 30] to affect enteric nervous and immune systems. SCFAs can directly affect Treg cells [52, 53], neutrophils [54], monocytes [55], and mast cell [56] through the GPRs expressed on them, which will modulate the immune homeostasis of the body. It has been shown in animal experiments that therapy with three microbiota-derived SCFAs (acetate, propionate, and butyrate) improved renal dysfunction in a sepsis model, largely through epigenetic modulation of the inflammatory process [32]. SCFAs were also sufficient to up-regulate serotonin (5-HT) [57]. 5-HT can promote immune function of leukocytes by either enhancing dendritic cell-mediated T-cell activation or affecting macrophage polarization and phagocytosis [58] (Fig. 4). This promising avenue of research requires future study.

Other therapies

The most common treatment for septic AKI is continuous renal replacement therapy (**CRRT**). CRRT can aid in **removal of uremic toxins**, sodium, and excessive volume. Thus, CRRT might positively impact gut wall edema and lessen the risk of bacterial translocation; future studies on CRRT should explore this possibility.

Conclusions

Many aspects of sepsis remain undefined, and the interplay between the gut and kidney during septic AKI remains an interesting avenue for investigation.



During sepsis, the combined effect of erosion of the mucus barrier, a shift in the composition and virulence of intestinal microbes, and the inability of the host epithelium to regulate its proliferative and apoptotic responses may lead to a tipping point in gut function where cascading inflammation drives AKI. **During AKI, the clearance of inflammatory mediators is decreased,** and metabolic products accumulate that can **increase systemic inflammation.** The continuous cycle of injury/amplification of inflammation can lead to devastating consequences. In theory, rational therapies aimed at restoring gut integrity, the microbiome, and the homeostatic balance between the two systems represents an exciting avenue in the battle against critical illness.

Abbreviations

5-HT: Serotonin; AKI: Acute kidney injury; ATP: Adenosine triphosphate; Bcl-2: B-cell lymphoma-2; BL: *Bifidobacterium longum*; CRRT: Continuous renal replacement therapy; ENS: Enteric nervous system; GPR: G-protein-coupled receptors; ICU: Intensive care unit; IECs: Intestinal epithelial cells; IL: Interleukin; JAM: Junctional adhesion molecules; LGG: *Lactobacillus rhamnosus* GG; LPS: Lipopolysaccharide; MCP-1: Monocyte chemo attractant protein-1; MLCK: Myosin light chain kinase; mTOR: Mechanistic target of rapamycin; NK: Natural killer; PRR: Pattern recognition receptor; SCFA: Short-chain fatty acid; SDD: Selective decontamination of the digestive tract; TLRs: Toll-like receptors; TNF- α : Tumor necrosis factor α ; Treg: Regulatory T; ZO-1: Zonulaoccludens 1

Authors' contributions

JZ, CR, and KD contributed to manuscript writing and editing. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Emergency and Critical Care Medicine, The Second Hospital of Jilin University, Changchun, China. ²Department of Internal Medicine and Nephrology, King Abdulaziz University, Jeddah, Saudi Arabia. ³International Renal Research Institute of Vicenza (IRRV), Vicenza, Italy. ⁴Division of Nephrology, University of Virginia Health System, Charlottesville, VA, USA. ⁵Department of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, Vicenza, Italy. ⁶Department of Nephrology and Research, Sir Ganga Ram Hospital, New Delhi, India.

Received: 31 January 2018 Accepted: 13 April 2018

Published online: 03 May 2018

References

- Mandelbaum T, Scott DJ, Lee J, et al. Outcome of critically ill patients with acute kidney injury using the Acute Kidney Injury Network criteria. *Crit Care Med*. 2011;39(12):2659–64. <https://doi.org/10.1097/CCM.0b013e3182281f1b>.
- Uchino S. Acute renal failure in critically ill patients: a multinational, multicenter study. *JAMA*. 2005;294(7):813. <https://doi.org/10.1001/jama.294.7.813>.
- Chao C-T, Hou C-C, Wu V-C, et al. The impact of dialysis-requiring acute kidney injury on long-term prognosis of patients requiring prolonged mechanical ventilation: nationwide population-based study. *PLoS One*. 2012;7(12):e50675. <https://doi.org/10.1371/journal.pone.0050675>.
- Bagshaw SM, Laupland KB, Doig CJ, et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. *Crit Care*. 2005;9(6):R700–9. <https://doi.org/10.1186/cc3879>.
- Hoste EAJ, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. *Intensive Care Med*. 2015;41(8):1411–23. <https://doi.org/10.1007/s00134-015-3934-7>.
- Gómez H, Kellum JA. Sepsis-induced acute kidney injury. *Curr Opin Crit Care*. 2016;22(6):546–53. <https://doi.org/10.1097/MCC.0000000000000356>.
- Linkermann A, Chen G, Dong G, Kunzendorf U, Krautwald S, Dong Z. Regulated cell death in AKI. *J Am Soc Nephrol*. 2014;25(12):2689–701. <https://doi.org/10.1681/ASN.2014030262>.
- Murugan R, Wen X, Shah N, et al. Plasma in inflammatory and apoptosis markers are associated with dialysis dependence and death among critically ill patients receiving renal replacement therapy. *Nephrol Dial Transpl*. 2014; 8(10):1854–64. <https://doi.org/10.1093/ndt/gfu051>.
- Gómez H, Kellum JA, Ronco C. Metabolic reprogramming and tolerance during sepsis-induced AKI. *Nat Rev Nephrol*. 2017;13(3):143–51. <https://doi.org/10.1038/nrneph.2016.186>.
- Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. *Cell*. 2016;164(3):337–40. <https://doi.org/10.1016/j.cell.2016.01.013>.
- Häbes QLM, van Ede L, Gerretsen J, Kox M, Pickkers P. Norepinephrine contributes to enterocyte damage in septic shock patients; a prospective cohort study. *Shock*. 2017;75(6):1. <https://doi.org/10.1097/SHK.0000000000000955>.
- Dominguez JA, Coopersmith CM. Can we protect the gut in critical illness? The role of growth factors and other novel approaches. *Crit Care Clin*. 2010; 26(3):549–65. <https://doi.org/10.1016/j.ccc.2010.04.005>.
- Mittal R, Coopersmith CM. Redefining the gut as the motor of critical illness. *Trends Mol Med*. 2014;20(4):214–23. <https://doi.org/10.1016/j.molmed.2013.08.004>.
- Turner JR. Intestinal mucosal barrier function in health and disease. *Nat Rev Immunol*. 2009;9(11):799–809. <https://doi.org/10.1038/nri2653>.
- Zahs A, Bird MD, Ramirez L, Turner JR, Choudhry MA, Kovacs EJ. Inhibition of long myosin light-chain kinase activation alleviates intestinal damage after binge ethanol exposure and burn injury. *Am J Physiol Gastrointest Liver Physiol*. 2012;303(6):G705–12.
- Vaziri ND, Yuan J, Rahimi A, Ni Z, Said H, Subramanian VS. Disintegration of colonic epithelial tight junction in uremia: A likely cause of CKD-associated inflammation. *Nephrol Dial Transplant*. 2012;27(7):2686–93. <https://doi.org/10.1093/ndt/gfr624>.
- Vaziri ND, Yuan J, Norris K. Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in CKD. *Am J Nephrol*. 2014;37(1):1–6. <https://doi.org/10.1159/000345969.Role>.
- El-Achkar TM, Huang X, Plotkin Z, Sandoval RM, Rhodes GJ, Dagher PC. Sepsis induces changes in the expression and distribution of Toll-like receptor 4 in the rat kidney. *Am J Physiol Ren Physiol*. 2006;290(5):F1034–43. <https://doi.org/10.1152/ajprenal.00414.2005>.
- Neal MD, Sodhi CP, Jia H, et al. Toll like receptor 4 is expressed on intestinal stem cells and regulates their proliferation and apoptosis via the p53-upregulated modulator of apoptosis. *J Biol Chem*. 2012;287(44):37296–308. <https://doi.org/10.1074/jbc.M112.375881>.
- Neal MD, Sodhi CP, Dyer M, et al. A critical role for TLR4 induction of autophagy in the regulation of enterocyte migration and the pathogenesis of necrotizing enterocolitis. *J Immunol*. 2013;190(7):3541–51. <https://doi.org/10.4049/jimmunol.1202264>.
- Dominguez JA, Vithayathil PJ, Khalilova L, et al. Epidermal growth factor improves survival and prevents intestinal injury in a murine model of pseudomonas aeruginosa pneumonia. *Shock*. 2011;36(4):381–9. <https://doi.org/10.1097/SHK.0b013e31822793c4>.
- Chang M, Alsaigh T, Kistler EB, Schmid-Schönbein GW. Breakdown of Mucin as barrier to digestive enzymes in the ischemic rat small intestine. *PLoS One*. 2012;7(6):1–12. <https://doi.org/10.1371/journal.pone.0040087>.
- Mazmanian SK, Round JL, Kasper D. A microbial symbiosis factor prevents inflammatory disease. *Nature*. 2008;453(7195):620–5.
- Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. *Crit Care Med*. 1999;27(7):1230–51. <https://doi.org/10.1097/00003246-199907000-00002>.
- Cho I, Blaser MJ. Applications of next-generation sequencing: The human microbiome: at the interface of health and disease. *Nat Rev Genet*. 2012; 13(4):260–70. <https://doi.org/10.1038/nrg3182>.
- Ojima M, Motooka D, Shimizu K, et al. Metagenomic analysis reveals dynamic changes of whole gut microbiota in the acute phase of intensive care unit patients. *Dig Dis Sci*. 2016;61(6):1628–34. <https://doi.org/10.1007/s10620-015-4011-3>.
- Defazio J, Fleming ID, Shakhsheer B, Zaborina O, Alverdy JC. The opposing forces of the intestinal microbiome and the emerging pathobiome. *Surg Clin North Am*. 2014;94(6):1151–61. <https://doi.org/10.1016/j.suc.2014.08.002>.
- Feng Y, Balls MW, Xiao W, Miyasaka E, Herman RS, Teitelbaum DH. Loss of enteral nutrition in a mouse model results in intestinal epithelial barrier dysfunction. *Ann N Y Acad Sci*. 2012;1258(1):71–7. <https://doi.org/10.1111/j.1749-6632.2012.06572.x>.
- Hayakawa M, Asahara T, Henzan N, et al. Dramatic changes of the gut flora immediately after severe and sudden insults. *Dig Dis Sci*. 2011;56(8):2361–5. <https://doi.org/10.1007/s10620-011-1649-3>.
- Charney AN, Micić L, Egnor RW. Nonionic diffusion of short-chain fatty acids across rat colon. *Am J Phys*. 1998;274(3):G518–24. <https://doi.org/10.1152/ajpgi.1998.274.3.G518>.
- Kamada N, Seo SU, Chen GY, Nunez G. Role of the gut microbiota in immunity and inflammatory disease. *Nat Rev*. 2013;13(5):321–35. <https://doi.org/10.1038/nri3430>.
- Andrade-Oliveira V, Amano MT, Correa-Costa M, et al. Gut bacteria products prevent AKI induced by ischemia-reperfusion. *J Am Soc Nephrol*. 2015;26(8): 1877–88. <https://doi.org/10.1681/ASN.2014030288>.
- Deitch EA. Gut lymph and lymphatics: a source of factors leading to organ injury and dysfunction. *Ann N Y Acad Sci*. 2010;1207(Suppl):E103–11. <https://doi.org/10.1111/j.1749-6632.2010.05713.x>.
- Purohit V, Bode JC, Bode C, et al. Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. *Alcohol*. 2008;42(5):349–61. <https://doi.org/10.1016/j.alcohol.2008.03.131>.
- Bellot P, Francés R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. *Liver Int*. 2013;33(1):31–9. <https://doi.org/10.1111/liv.12021>.
- Mizuno T, Yokoyama Y, Nishio H, et al. Intraoperative bacterial translocation detected by bacterium-specific ribosomal RNA-targeted reverse-transcriptase polymerase chain reaction for the mesenteric lymph node strongly predicts postoperative infectious complications after major hepatectomy for. *Ann Surg*. 2010;252(6):1013–9. <https://doi.org/10.1097/SLA.0b013e3181f3f355>.
- Sumagin R, Robin AZ, Nusrat A, Parkos CA. Transmigrated neutrophils in the intestinal lumen engage ICAM-1 to regulate the epithelial barrier and

- neutrophil recruitment. *Mucosal Immunol.* 2014;7(4):905–15. <https://doi.org/10.1038/mi.2013.106>.
38. Fujii K, Shibata M, Nakayama Y, et al. A heart-brain-kidney network controls adaptation to cardiac stress through tissue macrophage activation. *Nat Med.* 2017;23(5):611–22. <https://doi.org/10.1038/nm.4326>.
 39. Schuijt TJ, van der Poll T, de Vos WM, Wiersinga WJ. The intestinal microbiota and host immune interactions in the critically ill. *Trends Microbiol.* 2013;21(5):221–9. <https://doi.org/10.1016/j.tim.2013.02.001>.
 40. Waltz P, Carchman E, Gomez H, Zuckerbraun B. Sepsis results in an altered renal metabolic and osmolyte profile. *J Surg Res.* 2016;202(1):8–12. <https://doi.org/10.1016/j.jss.2015.12.011>.
 41. Wang J, Wei Q, Wang CY, Hill WD, Hess DC, Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. *J Biol Chem.* 2004;279(19):19948–54. <https://doi.org/10.1074/jbc.M313629200>.
 42. wasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. *Nat Immunol.* 2015;16(4):343–53. <https://doi.org/10.1038/ni.3123>.
 43. Gordon S, Plüddemann A, Martinez Estrada F. Macrophage heterogeneity in tissues: Phenotypic diversity and functions. *Immunol Rev.* 2014;262(1):36–55. <https://doi.org/10.1111/immr.12223>.
 44. Gabanyi I, Muller PA, Feighery L, Oliveira TY, Costa-Pinto FA, Mucida D. Neuro-immune interactions drive tissue programming in intestinal macrophages. *Cell.* 2016;164(3):378–91. <https://doi.org/10.1016/j.cell.2015.12.023>.
 45. Sica A, Mantovani A. Macrophage plasticity and polarization: In vivo veritas. *J Clin Invest.* 2012;122(3):787–95. <https://doi.org/10.1172/JCI59643>.
 46. Xing L, Genhua M, Chunmei S, et al. Role of M2 macrophages in sepsis-induced acute kidney injury. *Shock.* 2017;1 <https://doi.org/10.1097/SHK.0000000000001006>.
 47. de Smet AMGA, Kluytmans JAJW, Cooper BS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. *N Engl J Med.* 2009;360(1):20–31. <https://doi.org/10.1056/NEJMoa0800394>.
 48. Price R, MacLennan G, Glen J, SuDDICU Collaboration. Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-analysis. *BMJ.* 2014;348:g2197. <https://doi.org/10.1136/bmj.g2197>.
 49. Khalilova L, Frank DN, Dominguez JA, Wischmeyer PE. Probiotic administration reduces mortality and improves intestinal epithelial homeostasis in experimental sepsis. *Anesthesiology.* 2013;119(1):166–77. <https://doi.org/10.1097/ALN.0b013e318291c2fc>.
 50. Shimizu K, Ogura H, Asahara T, et al. Probiotic/synbiotic therapy for treating critically ill patients from a gut microbiota perspective. *Dig Dis Sci.* 2013;58(1):23–32. <https://doi.org/10.1007/s10620-012-2334-x>.
 51. van Nood E, Vriee A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med.* 2013;368(5):407–15. <https://doi.org/10.1056/NEJMoa1205037>.
 52. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science.* 2013;341(6145):569–73. <https://doi.org/10.1126/science.1241165>.
 53. Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous *Clostridium* species. *Science.* 2011;331(6015):337–41. <https://doi.org/10.1126/science.1198469>.
 54. Carretta MD, Conejeros I, Hidalgo MA, Burgos RA. Propionate induces the release of granules from bovine neutrophils. *J Dairy Sci.* 2013;96(4):2507–20. <https://doi.org/10.3168/jds.2012-6111>.
 55. Digby JE, Martinez F, Jefferson A, et al. Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. *Arterioscler Thromb Vasc Biol.* 2012;32(3):669–76. <https://doi.org/10.1161/ATVBAHA.111.241836>.
 56. Diakos C, Prieschl EE, Säemann MD, et al. n-Butyrate inhibits Jun NH(2)-terminal kinase activation and cytokine transcription in mast cells. *Biochem Biophys Res Commun.* 2006;349(2):863–8. <https://doi.org/10.1016/j.bbrc.2006.08.117>.
 57. Yano JM, Yu K, Donaldson GP, et al. Indigenous bacterica from the gut microbiota regulate host serotonin biosynthesis. *Cell.* 2015;161(2):264–76. <https://doi.org/10.1016/j.cell.2015.02.047>. *Indigenous*.
 58. de las Casas-Engel M, Dominguez-Soto A, Sierra-Filardi E, et al. Serotonin skews human macrophage polarization through HTR2B and HTR7. *J Immunol.* 2013;190(5):2301–10. <https://doi.org/10.4049/jimmunol.1201133>.